Merck Sharp + Dohme Corp.

Andrew J Leyhane

Anandan Palani

Robert G Aslanian

Xianhai Huang

Kevin D McCormick

Dong Xiao

Hongjun Zhang

Younong Yu

Phieng Siliphaivanh

Joey Lee Methot

Christopher W Boyce

Robert D Mazzola, Jr

Purakkattle J Biju

Ashwin Umesh Rao

Qin Jiang

Jun Qin

Elizabeth Helen Kelley

Li Dong

Pawan Dhondi

Jolicia Polivina Gauuan

Brian Alexander McKittrick

Xiao Chen

John P Caldwell

Wei Zhou

Haiqun Tang

Salem Fevrier

Henry M Vaccaro

Ning Shao

Rachel Nicola MacCoss

Jie Wu

Sylvia Joanna Degrado

William Colby Brown

Robert D Mazzola

Rachel N Maccoss

Kevin D Mccormick

Brian A Mckittrick

Pawan K Dhondi

Purakkattle Johny Biju

Joe Lee Method

Kevin D Mccormic

Robert George Aslanian

The invention provides certain quinoxalines and aza-quinoxalines of the Formula (I), and their pharmaceutically acceptable salts, wherein J, J, R, R, R, R, R, R, R, R, X, Y, b, n, and q are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTHfunction. 

[object Object]

This application provides for compounds of the formula Formula I or a pharmaceutically acceptable salt thereof, wherein the individual variables are defined herein, as well as processes to prepare these compounds, pharmaceutical compositions comprising the same and their use in treating disease state associated with the CRTHreceptor. 

Growing community of inventors

Latham, NY, United States of America

Andrew J Leyhane